Top 10 Insider Purchases Last Month

3. Metsera, Inc. (NASDAQ:MTSR)

Total value of insider purchases in February: $94,219,956.00

Market capitalization: $2.64 billion

The third among the stocks with the highest value of insider purchases in February is a clinical-stage biotechnology company, Metsera. The New York City-based company is developing injectable and oral nutrient-stimulated hormone analog peptides to treat obesity and metabolic diseases. It was founded in 2022 by Population Health Partners and ARCH Venture Partners.

In January, the company shared promising results from a 12-week Phase 2a clinical trial of its leading drug candidate, MET-097i, which is being developed as a potential once-monthly injectable treatment for obesity. The trial showed that MET-097i led to significant weight loss in participants, with some shedding up to 20% of their body weight, and was generally well tolerated, with only mild side effects. The company intends to conduct additional studies in 2025.

The company went public at the beginning of February. During its IPO, three insiders purchased a total of $94.22 million worth of Metsera shares at a price of $18 per share. Since then, the stock gained 4.40% and is now trading at $25.34 per share.

Based on assessments from four analysts, Metsera stock has an average rating of “Strong Buy,” writes StockAnalysis. The 12-month price target is $47.00, representing an anticipated increase of 85.88% from its current price.